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Abstract: Since being introduced to epidemiology in 2000, marginal 
structural models have become a commonly used method for causal 
inference in a wide range of epidemiologic settings. In this brief 
report, we aim to explore three subtleties of marginal structural mod-
els. First, we distinguish marginal structural models from the inverse 
probability weighting estimator, and we emphasize that marginal 
structural models are not only for longitudinal exposures. Second, we 
explore the meaning of the word “marginal” in “marginal structural 
model.” Finally, we show that the specification of a marginal struc-
tural model can have important implications for the interpretation of 
its parameters. Each of these concepts have important implications 
for the use and understanding of marginal structural models, and thus 
providing detailed explanations of them may lead to better practices 
for the field of epidemiology.
(Epidemiology 2018;29: 352–355)
Marginal structural models (MSM), and their esti-mation using inverse probability weighted (IPW) 
estimating equations, were introduced by Robins,1 and to 
the epidemiology community in two papers published in 
2000.2,3 MSMs have become common in the epidemiologic 
literature, and have been applied to a range of subjects, 
from infectious diseases4 to maternal and child health5 to 
social6 epidemiology.
This brief report aims to explore three subtleties 
of MSMs. We assume that the reader is familiar with IPW 
approaches (if not we recommend Sato and Matsuyama,7 
Cole and Hernán,8 and Cole and Hernán9) and MSMs (we rec-
ommend Robins et al.,2 Hernán et al.,3 Petersen et al.,10 and 
Hernán et al.11).
MARGINAL STRUCTURAL MODELS ARE 
DISTINCT FROM INVERSE PROBABILITY 
WEIGHTING
The form of a MSM is E Y f aa( ) = ( );θ , where
a a a aT= …( )0 1, , ,  is the full exposure history, Y a  is the out-
come that the subject would have experienced under exposure 
history a ,  andθ is a set of parameters.2 While often consid-
ered a tool for longitudinal, time-varying exposures, MSMs 
can be used in point-exposure settings. For example, we 
might use the model E Y aa( ) = +α θ for dichotomous a and
 continuousY ; andθ would be interpreted as the average treat-
ment effect12 of a  on Y .
The parameterθ can be estimated in several ways, one 
of which is IPW estimating equations. The distinction between 
MSMs and IPW lies in the difference between a parameter 
(also referred to as an estimand—the thing we are trying to 
estimate—in this case, θ ) and an estimator (the method or 
algorithm we are using to estimate it). Estimands may fur-
ther be categorized as causal, in which case they may be inter-
preted as the effect of an intervention, and purely statistical, 
in which case it is a parameter or feature of a distribution that 
may lack a causal interpretation. IPW is an estimator, but not 
the only estimator, for the causal estimand (the parameter of 
the MSM). The distinction between IPW and MSMs (and esti-
mators and estimands more generally) is important, as other 
methods besides IPW can be used to estimate MSM param-
eters, such as maximum likelihood10,13 or targeted maximum 
likelihood estimation.14
THE “MARGINAL” OF “MARGINAL 
STRUCTURAL MODELS” IS NOT THE 
“MARGINAL” OF STANDARDIZED ESTIMATES
Typically in statistical and epidemiologic literature, 
a model is considered marginal if it is not conditional on 
covariates, otherwise it is conditional.15 A regression model 
that includes covariates in the linear predictor to control for 
confounding is a conditional model. In contrast, standardiza-
tion methods also control for confounding, but produce mar-
ginal estimates with respect to the covariates. Because IPW 
is a standardization method, it is easy to assume that the mar-
ginal in MSM signifies “unconditional on covariates”; this is 
often true but not the original intended meaning. In the first 
paper to introduce MSMs to epidemiologists, Robins et al.2 
state “[MSMs] are marginal models, because they model the 
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marginal distribution of the counterfactual random variables 
Y1 and Y0 rather than the joint distribution.” In other words, 
MSMs are marginal because they model the marginal distri-
bution of the potential outcomes. The Appendix explores this 
distinction in more detail.
Further, when conditional causal effects are of interest 
or more precise parameter estimation is desired (through the 
use of stabilized weights), MSMs can be conditional on base-
line covariates, yet are still referred to as MSMs because they 
model the marginal distributions of the potential outcomes; 
indeed, this is what was done in the companion article3 to 
the Robins et al. introduction excerpted above2. Moreover, 
history-adjusted MSMs can condition on time-varying con-
founders.16 Understanding this distinction is important for 
interpreting and implementing MSMs, for instance by help-
ing researchers recognize that their MSMs can be conditional 
models, or that the estimated parameters may not represent 
average causal effects for their entire study population.
MSM MISSPECIFICATION CAN LEAD TO THE 
RIGHT ANSWER TO THE WRONG QUESTION
So-called causal inference methods are often used to 
analyze observational studies like randomized trials. In partic-
ular, MSM parameters are often estimated for studying effects 
analogous to a per-protocol effect from a trial.11 To interpret 
the estimates from a MSM as emulating such an analysis it is 
necessary to properly specify the structural model.
Consider the causal diagram in the Figure. This diagram 
represents a study in which participants are randomized to ini-
tiate treatment at time 1 ( ),A1 and, depending on response to 
treatment (or lack of treatment) ( Z ), decide whether or not 
to stay on treatment (or initiate treatment) at time 2 ( ).A2
Subjects can experience the outcome of interest at the end of 
time 1 ( )Y1 or the end of time 2 ( ).Y2  Additionally, the effect 
of treatment is delayed, so time 1 treatment only effects the 
outcome at time 2, and treatment only operates through the 
treatment response, Z.  For simplicity, we will assume that all 
variables are dichotomous.
The probability of the outcome by time 2 under each poten-
tial exposure history can be modeled with an MSM of the form





1 1 1=( ) = − −( )
=
∏ ,
where h P Y Yt t t
a a a= = =−( | )1 01  is the discrete-time haz-
ard for the outcome at time t (the risk of experiencing the out-
come at time t conditional on not experiencing the outcome by 
t −1) under exposure regime a . The MSM specification thus 
only requires specifying a model for the discrete-time hazard. 
A nonparametric MSM for the discrete-time hazard is
h
a t
a a a a tt
a =
+ =
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If such a model is used and the weights are properly 
estimated, the parameters of this MSM can be validly esti-
mated using IPW, and the results of the analysis will mimic 
the results of a trial in which subjects are randomized to expo-
sure regimens at baseline.
The MSMs often fit, such as the marginal structural Cox 
models in Hernán et al.3 and Cole et al.,4 and the IPW survival 
curves in Westreich et al 2010,17 are somewhat different. The 
MSM above accounts for the full history of exposure, whereas 
the MSMs used in the papers mentioned here only account for 
the most recent exposure. An example of a parametric MSM 






















a and h at′ ( )  are not necessarily equal.
If exposures besides the most recent impact the outcome, then 
h at′ ( )  may be misspecified and may not represent the true 
discrete-time hazard at time t  under exposure history a  If 
only the most recent exposure has an effect on the outcome, 
then ht
a  and h at′ ( )  will agree. Of note, when the MSM is
misspecified, the use of stabilized weights versus unstabilized 
weights can change the parameter being estimated.18
Consider the scenario described in the Table. In this 
case, the results obtained from estimating (1) with unstabi-
lized IPW (in an infinitely large population with non-para-
metrically estimated weights) give a causal risk difference 
for always versus never exposed of 0.44, whereas the results 
obtained from estimating (2) with IPW under similar con-
ditions give 0.23 (details of these calculations are described 
in the eAppendix; http://links.lww.com/EDE/B321). The risk 
difference of 0.44 can be interpreted as the difference in the 
risk of the outcome if all subjects had been exposed in both 
periods compared with if they had been unexposed in both 
periods. However, the risk difference of 0.23 is interpreted 
differently, as described in Westreich et al.,17 as the result of 
Z
FIGURE. The causal diagram used in the example.
TABLE. The Dependency Structure Used in the Illustrative 
Example
P A1 1 0 5=( ) = .
P Y A a a1 1 1 11 0 1 0 1= =( ) = +| . .
P Z A a Y a= = =( ) = +1 0 0 1 0 41 1 1 1| , . .
P A Z z A a Y z2 1 1 11 0 0 2 0 6= = = =( ) = +| , , . .
P Y A a A a Z z Y a z2 2 2 1 1 1 21 0 0 1 0 2 0 6= = = = =( ) = + +| , , , . . .
a trial in which participants are randomly assigned exposure 
in the first period and are then rerandomized to exposure in 
the second period. As described in Cole et al.,19 this risk dif-
ference could equivalently be interpreted as the result from 
a trial in which participants are randomized at baseline to 
begin exposure in the first period, second period, or not at 
all. It is therefore incorrect to interpret the risk difference of 
0.23 as a comparison of the outcome among always-treated 
versus never-treated subjects. One suggested way to reduce 
the bias when using (2) is to change the time scale to time on 
treatment.17
This example highlights an important concept: proper 
specification of the MSM can dictate the interpretation of the 
results. As demonstrated here, with a misspecified MSM, the 
results may still have a causal interpretation, but they may not 
necessarily represent any meaningful or interesting quantity 
and may be different than the quantity the investigator seeks 
to estimate.
DISCUSSION
In this brief report, we highlighted and explained 
three concepts about MSMs and IPW. Though these ideas 
may seem subtle, they can have important implications for 
the use and interpretation of MSMs and IPW. First, it is 
important to know that estimators besides IPW can be used 
to estimate the parameters of MSMs. Second, it is impor-
tant to distinguish between estimates that are conditional on 
covariates versus those that are marginal, and not to assume 
that because the word “marginal” is in the name marginal 
structural model that the estimate is marginal in all senses. 
Finally, researchers must carefully specify their MSM and 
ensure that they properly interpret their results. We hope 
that by elucidating these issues, epidemiologists will gain 
a deeper understanding into these important methods for 
causal inference.
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APPENDIX
The Meaning Of Marginal In Marginal 
Structural Models
Here, we elaborate on what it means for a model to be 
marginal with respect to the potential outcomes. Consider 
Table A1:
The rows represent the potential outcome for an indi-
vidual had they not been exposed, and the columns repre-
sent the potential outcomes for an individual had they been 
exposed. Note that the four interior cells of the table corre-
spond to the proportions of the four causal types described by 
Greenland and Robins,20 specifically subjects in the upper left 
are “doomed” because they experience the outcome regard-
less of the value of X (Y0 = Y1 = 1), those in the upper right 
are “helped” because without the intervention they experience 
the outcome (Y0 = 1) but with the intervention they do not 
experience the outcome (Y1 = 0), those in the bottom left are 
“harmed,” and those in the bottom right are “immune.” The 
margins on the right and on bottom are the proportion of the 
population that would have each level of the outcome if they 
had been unexposed and exposed, respectively: for example, 
the margin Pr(Y1 = 1) is the proportion of the population that 
would experience the outcome if, possibly counter to fact, 
they had been exposed, regardless of what they would experi-
ence if they had been unexposed.
Because only one of the potential outcomes for any given 
individual can be observed, it is difficult to see how one could 
estimate any of the quantities from the interior cells of the table. 
Intuitively, this means that we cannot determine how many 
individuals are doomed, helped, harmed, or immune without 
further (unverifiable) assumptions. However, under a sufficient 
set of identification conditions, which might include condi-
tional exchangeability, positivity, consistency, and no exposure 
or outcome measurement error,21,22 it is possible to estimate 
the quantities on the margins of the table using observed data 
(including data observed in a randomized trial), namely the 
proportion of individuals who would experience each level of 
the outcome if they had been exposed, and the proportion who 
would experience each level of the outcome if they had been 
unexposed. The fact that MSMs estimate a contrast in the latter 
quantities, which correspond to the margins of the distribution, 
is what is meant by the word marginal in this context.2
TABLE A1. Illustration of “Marginal” for Marginal Structural 
Models
Y1 = 1 Y1 = 0 Margin of Y0
Y0 = 1 Pr(Y0 = 1, Y1 = 1) Pr(Y0 = 1, Y1 = 0) Pr(Y0 = 1)
Y0 = 0 Pr(Y0 = 0, Y1 = 1) Pr(Y0 = 0, Y1 = 0) Pr(Y0 = 0)
Margin of Y1 Pr(Y1 = 1) Pr(Y1 = 0)
